Pharmaceutical Sales Jobs
|
One-Stop Resume Posting to Over 75 Career Sites. Click Here |
|
|
|
|
Our list of pharmaceutical sales jobs consists of a page for each state, and each page combines the results from several job search engines. Our paradigm is similar to the meta-search engines like Dogpile, except here we combine the results from job search engines as opposed to regular search engines.
Here we also provide to the pharmaceutical sales representative informative articles, useful statistics, videos, a selection of books, and current pharmaceutical industry news. The pharmaceutical sales jobs listed here are in the form of RSS feeds, and will be automatically updated when new jobs become available. This site is produced by IntellegoJobs, a division of Intellego Web Publishing.
The following data should be interesting to the pharmaceutical sales rep who resides within the United States. This data comes from the Bureau of Labor Statistics.
Sales Representatives for Technical and Scientific Products - Statistics (Bureau of Labor Statistics)
States with the highest concentration of sales representatives for technical and scientific products with annual salary:
(highest at top)
New Hampshire $77,120
Massachusetts $88,550
Utah $74,800
South Dakota $63,310
Arizona $61,560
Top paying states for sales representatives for technical and scientific products with annual salary:
(highest at top)
Delaware $91,220
Massachusetts $88,550
Maryland $85,790
Minnesota $85,090
District of Columbia $85,050
Mean annual salary for sales representatives for technical and scientific products:
$76,460
Metropolitan areas with the highest concentration of sales representatives for technical and scientific products with annual salary:
Nashua, NH-MA NECTA Division $78,780
Framingham, MA NECTA Division $74,970
Lowell-Billerica-Chelmsford, MA-NH NECTA Division $99,010
San Jose-Sunnyvale-Santa Clara, CA $100,000
Lake County-Kenosha County, IL-WI Metropolitan Division $88,440
Top paying metropolitan areas for sales representatives for technical and scientific products:
Sacramento—Arden-Arcade—Roseville, CA $102,360
San Jose-Sunnyvale-Santa Clara, CA $100,000
Lowell-Billerica-Chelmsford, MA-NH NECTA Division $99,010
Bridgeport-Stamford-Norwalk, CT $98,520
Wenatchee, WA $98,100
Industries with the highest level of employment for the sales representatives for technical and scientific products:
(highest at top)
Professional and Commercial Equipment and Supplies Merchant Wholesalers
Wholesale Electronic Markets and Agents and Brokers
Drugs and Druggists’ Sundries Merchant Wholesalers
Electrical and Electronic Goods Merchant Wholesalers
Computer Systems Design and Related Services
Top paying industries for sales representatives for technical and scientific products
Satellite Telecommunications $107,050
Other Professional, Scientific, and Technical Services $102,100
Other Motor Vehicle Dealers $97,980
Other Telecommunications $92,770
Computer and Peripheral Equipment Manufacturing $91,080
Training and requirements needed for the sales representatives for technical and scientific products:
Today, more frequently then not, employers are hiring sales representatives with a college degree, regardless of the type of product you are selling. If you want to be a pharmaceutical sales representative, indeed you should have a college degree. As a matter of fact, in most cases, you need a college degree if you want to sell any technical or scientific product.
The usual characteristics of any successful salesman such as a friendly personality, the ability to sell, and familiarity with the brand are also looked for in the pharmaceutical sales representative. Also, more so then many other sales positions, you need to sell the product to the physician within a very short period of time, usually a matter of minutes. This is simply because most doctors do not not have the time to listen to a long sales pitch.
In the pharmaceutical industry, it is essential that the sales rep have a complete and thorough knowledge of the drug he or she is selling. This includes side effects, interactions, efficacy, clinical trial data and more. Therefore extensive knowledge from the disciplines of chemistry and human biology are essential, along with a thirst for learning and understanding. Knowledge about drugs and medicines is also picked up from seminars and on the job training.
For more information about training required for the pharmaceutical sales representative in the United States go to Occupational Outlook Handbook provided by the Bureau of Labor Statistics.
Pharmaceutical Sales Jobs - Employment Growth and Outlook
Overall, sales employment growth in the United States is expected to be about average. Employment growth is expected to be around 9% between 2006 and 2016, which is average relative to all other occupations. It should be noted that this is for all sales positions.
As the elderly population in the United States continues to grow in size, their need for various medicines will also continue to grow. Drug companies will need to produce medicines with a high level of efficacy and fewer side effects in order to meet the medical needs of an increasing elderly population. Because the pharmaceutical sales representative is the interfacing pipeline between the drug company and the physician, this type of sales representative should continue to see increasing employment opportunities. Therefore, employment growth for the pharmaceutical sales representative should be greater then that which is expected for other sales positions.
It should also be noted that competition for technical and scientific product sales positions will be keen, including pharmaceutical sales representatives. This is because of the higher salary offered to individuals who hold these positions.
Source for the above data:
E-Mail your Resume and Cover Letter to 1000’s of Headhunters, Click Here
Pharmaceutical Sales Jobs - Videos About the Resume
|
|
The following is a current listing of job openings in the United States for the pharmaceutical sales representative.
Pharmaceutical Sales Jobs - Listed by State - Updated Daily
Pharmaceutical Industry News
Pharma Industry / Biotech Industry News From Medical News Today
Copyright 2010 Medical News Today
Latest Health News and Medical News posted throughout the day, every day.
The Potential For Using Algae To Produce Human Therapeutic Proteins
Pharmaceutical companies could substantially reduce the expense of costly treatments for cancer and other diseases produced from mammalian or bacterial cells by growing these human therapeutic proteins in algae - rapidly growing aquatic plant cells that have recently gained attention for their ability to produce biofuels...
Computer Reminders For Physicians Less Effective Than Expected
Computer reminders to physicians regarding prescribing produce much smaller improvements than initially expected, found a study in CMAJ (Canadian Medical Association Journal). Computerized systems for entering orders and electronic medical records are the two most widely recommended improvements in health care...
Science World Charmed By Snake Venom
The King Cobra continues to weave its charm with researchers identifying a protein in its venom with the potential for new drug discovery and to advance understanding of disease mechanisms. The novel protein named haditoxin has been described in the prestigious Journal of Biological Chemistry (March 12, 2010)...
Nektar Announces Positive Phase 2 Clinical Data From First Stage Of NKTR-102 Study In Women With Platinum-Resistant Ovarian Cancer
Nektar Therapeutics (Nasdaq: NKTR) announced preliminary progression-free survival data from the first stage of a two-stage Phase 2 clinical study evaluating single-agent treatment with NKTR-102 in women with platinum-resistant ovarian cancer...
NOVAVAX Completes Enrollment Of Pivotal H1N1 Influenza Vaccine Clinical Trial In Mexico
Novavax, Inc. (Nasdaq: NVAX) announced that the enrollment of over 3,500 subjects in Mexico has been completed in Stage B of its pivotal 2009 H1N1 virus-like-particle (VLP) pandemic influenza vaccine study. With the 1,000 subjects already enrolled in Stage A of the trial, the enrollment in this pivotal trial is now complete with over 4,500 subjects...
Acologix Presents Data On Cartilage Regeneration By AC-100 At The 56th Annual Meeting Of The Orthopaedic Research Society
Acologix, Inc., a privately held biopharmaceutical company, announced the results of its latest preclinical study demonstrating that AC-100, its therapeutic product candidate derived from an endogenous human protein, promotes cartilage regeneration in a large animal model. The data will be presented by Dr. David M...
Peptimmune Announces Second Grant Of A United States Patent For PI-2301 Peptide Copolymer For Multiple Sclerosis
Peptimmune, Inc. a privately held biotechnology company, announced the grant of US Patent Number 7,655,221 (the '221 patent) which protects the target product profile for its PI-2301 peptide copolymer for the treatment of multiple sclerosis, and other autoimmune diseases. The '221 patent claims important treatment modalities for PI-2301 and related compounds...
Selective Automation A Must For Clinical Labs To Remain Competitive
While clinical laboratories are vital to the diagnostic industry, they are facing multiple challenges that will require increased automation in order for them to remain competitive...
Poniard Pharmaceuticals Presents Positive Survival Data From A Phase 2 Clinical Study Of Picoplatin In Metastatic Prostate Cancer
Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, announced the presentation of positive final data, including survival data, from the Company's Phase 2 clinical trial of picoplatin as a first-line therapy in men with metastatic castration-resistant (hormone-refractory) prostate cancer (CRPC)...
InterMune Announces Posting Of Briefing Documents For FDA Advisory Committee Meeting On Pirfenidone
InterMune, Inc. (Nasdaq: ITMN) announced that the U.S...
ISIS Initiates Phase 1 Clinical Trial Of ISIS-SOD1Rx In Patients With ALS
Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced that it has initiated a Phase 1 study of ISIS-SOD1Rx in patients with an inherited, aggressive form of Lou Gehrig's disease also known as familial amyotrophic lateral sclerosis (ALS). Approximately 20 percent of all familial ALS cases are caused by a mutant form of superoxide dismutase, or SOD1...
Phase III REGION-I Study Shows PEP005 (ingenol Mebutate) Gel 0.05% May Reduce Pre-Cancerous Skin Lesions In Patients With Actinic Keratosis
Specialty pharmaceutical company LEO Pharma announced that findings from a Phase III study evaluating PEP005 (ingenol mebutate) Gel 0.05% to treat actinic keratosis (AK), a common pre-cursor to skin cancer, were presented at the 68th Annual Meeting of the American Academy of Dermatology (AAD) (Scientific Session Poster Discussion: P105)...
FDA Approves Name Change For Heartburn Drug Kapidex
The U.S. Food and Drug Administration has approved a name change for the heartburn drug Kapidex (dexlansoprazole) to avoid confusion with two other medications - Casodex and Kadian. Effective in late April 2010, Takeda Pharmaceuticals North America Inc. will market Kapidex under the new name Dexilant...
2010 BIO International Convention Expected To Bring More Than $25 Million To Chicago
The Biotechnology Industry Organization announced that the 2010 BIO International Convention is expected to contribute more than $25 million to the local economy, according to estimates from the Chicago Convention and Tourism Bureau. The BIO International Convention returns to Chicago May 3-6 and is expected to draw 15,000 to 17,000 industry leaders from 48 states and 60 countries...
Key Caldolor(R) Orthopedic Data To Be Presented At American Academy Of Orthopaedic Surgeons' Annual Meeting
Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) announced that results from a clinical trial of Caldolor® (ibuprofen) Injection will be presented at the 2010 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS) in New Orleans, Louisiana...
Gynecologic Oncology Group Notifies CTI That Continuation Of GOG-212 Pivotal Trial Of OPAXIO Maintenance Therapy In Ovarian Cancer Is A Priority
Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced that CTI received a statement on March 1, 2010 from the Gynecologic Oncology Group (GOG) leadership that the phase III GOG-212 clinical trial of CTI's OPAXIO™ used as maintenance therapy for ovarian cancer remains a high priority and enrollment will continue...
Medtronic Named Among World's Most Innovative Companies By MIT Technology Review
Medtronic, Inc. (NYSE: MDT) announced that it has been selected as one of Massachusetts Institute of Technology (MIT) Technology Review's 50 most innovative companies. Known as TR50, the first annual list includes companies that Technology Review believes have demonstrated superiority in inventing technology and in using it both to grow their own business and transform how we live...
Dendreon Presents Updated IMPACT Results Confirming PROVENGE Improves Overall Survival In Patients With Metastatic Castrate-Resistant Prostate Cancer
Dendreon Corporation (Nasdaq: DNDN) announced updated results from its pivotal Phase 3 IMPACT (IMmunotherapy for Prostate AdenoCarcinoma Treatment) study demonstrating that PROVENGE® (sipuleucel-T) extends overall survival in men with metastatic, castrate-resistant (hormone-refractory) prostate cancer (CRPC)...
Cabazitaxel Increased Survival For Patients With Advanced Hormone-Refractory Prostate Cancer
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced results from a Phase 3 trial which demonstrated cabazitaxel, an investigational compound, plus prednisone/prednisolone significantly improved overall survival and progression-free survival in patients with metastatic (advanced) hormone-refractory prostate cancer whose disease progressed following treatment with docetaxel-based chemotherapy...
BIO Welcomes EU Decision On Biotech Crops
The Biotechnology Industry Organization (BIO) applauded today's announcement by the European Commission to authorize the cultivation of a biotech potato, as well as the commercialization of three varieties of biotech maize for food and feed uses and import and processing...
75 Percent Of Drug Companies Formally Manage Investigator-Initiated Trials
Investigator-initiated trials (IITs) provide companies with clinical data to expand scientific understanding of their drugs and reap a number of additional benefits. IIT management, however, can be challenging. Data collected by business intelligence firm Cutting Edge Information show that 75% of surveyed companies have some form of dedicated IIT management group in place...
Trius Therapeutics To Conform Protocol For Upcoming Torezolid Phosphate Phase 3 Trial With Newly Released FDA Draft Guidance
Trius Therapeutics, Inc. announced that on February 26th, 2010, the FDA issued new draft guidance on non-inferiority clinical trials that will apply to the design of the Company's proposed Phase 3 trials for its investigational antibacterial drug torezolid phosphate...
FDA Sets March 22 For ODAC Meeting To Review CTI's New Drug Application For Pixantrone
Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced that the U.S. Food and Drug Administration's ("FDA") Oncologic Drugs Advisory Committee ("ODAC") will review CTI's New Drug Application ("NDA") for pixantrone for the treatment of relapsed/refractory aggressive non-Hodgkin's lymphoma ("NHL") on March 22, 2010...
Vivus's Qnexa Will Become Decision Resources' Clinical Gold Standard In 2013 For The Treatment Of Obesity
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of obesity, Vivus's Qnexa (the phentermine/topiramate combination) will earn Decision Resources' proprietary clinical gold standard in 2013 and through 2018 following its anticipated U.S. approval for the disease in 2011...
New Data From Caldolor(R) Study In Burn Patients To Be Presented At 42nd Annual Meeting Of The American Burn Association
Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) announced that data from a recent study evaluating the safety and efficacy of Caldolor® (ibuprofen) Injection in treating pain and fever in hospitalized burn patients will be presented at the 42nd Annual Meeting of the American Burn Association in Boston...
7r5wk2sayt
Powered by FirstRSS Plugin
